Apolipoprotein E ε2 does not increase risk of early-onset sporadic Alzheimer's disease

W. K. Scott, A. M. Saunders, P. C. Gaskell, P. A. Locke, J. H. Growdon, L. A. Farrer, S. A. Auerbach, A. D. Roses, J. L. Haines, M. A. Pericak-Vance

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

We examined the association of apolipoprotein E (ApoE) genotype and the risk of early-onset Alzheimer's disease (AD) in 209 white early-onset sporadic cases (43% male) and 303 white controls (48% male) of similar age distribution. The risk of AD was significantly increased, relative to the 3/3 genotype, in people with the 4/4, 3/4, and 2/4 genotypes, controlling for age at time of examination and sex. The 2/3 genotype reduced slightly the risk of AD, although the effect was not statistically significant. We conclude, contrary to some previous reports, that the ApoE ε2 allele does not increase the risk of early-onset sporadic AD.

Original languageEnglish (US)
Pages (from-to)376-378
Number of pages3
JournalAnnals of neurology
Volume42
Issue number3
DOIs
StatePublished - Sep 1 1997
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Apolipoprotein E ε2 does not increase risk of early-onset sporadic Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Scott, W. K., Saunders, A. M., Gaskell, P. C., Locke, P. A., Growdon, J. H., Farrer, L. A., Auerbach, S. A., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1997). Apolipoprotein E ε2 does not increase risk of early-onset sporadic Alzheimer's disease. Annals of neurology, 42(3), 376-378. https://doi.org/10.1002/ana.410420317